Tiziana's intranasal foralumab met its Phase 2a MS endpoint at one dose but missed at another in non-active secondary progressive MS. See full results.
Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on November 2, 2026, creating Supernus, Inc. (Nasdaq: SUPN) with an 11-product central nervous system (CNS) portfolio ...
GPN Vaccines has closed a USD 10 million private placement to fund Phase II-enabling activities for its serotype-independent pneumococcal vaccine Gamma-PN, including cGMP batch manufacturing, ...
Karyopharm files Chapter 11 and names Ayrmid lead bidder in a court-supervised sale. Read how Ayrmid's bid affects its marketed drugs, pipeline and team.
FDA pushes back mitapivat sickle cell disease sNDA decision to February 1, 2027. Read how the REMS review affects Agios' PYRUKYND and what comes next.
Qure's AMT-130 Huntington's gene therapy has FDA Priority Review under Accelerated Approval, with a May 1, 2027 decision date. Read the details now.
InventisBio's nomelcitinib met its primary goal in a Phase III psoriasis trial. Read the topline results and the ongoing head-to-head study details now.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results